全文获取类型
收费全文 | 1325139篇 |
免费 | 101980篇 |
国内免费 | 4219篇 |
专业分类
耳鼻咽喉 | 16781篇 |
儿科学 | 43463篇 |
妇产科学 | 36383篇 |
基础医学 | 196201篇 |
口腔科学 | 35883篇 |
临床医学 | 128883篇 |
内科学 | 255614篇 |
皮肤病学 | 26367篇 |
神经病学 | 110965篇 |
特种医学 | 48113篇 |
外国民族医学 | 366篇 |
外科学 | 183629篇 |
综合类 | 28761篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 113315篇 |
眼科学 | 28918篇 |
药学 | 98545篇 |
6篇 | |
中国医学 | 3096篇 |
肿瘤学 | 75588篇 |
出版年
2019年 | 11626篇 |
2018年 | 16304篇 |
2017年 | 12291篇 |
2016年 | 13253篇 |
2015年 | 15199篇 |
2014年 | 20804篇 |
2013年 | 32064篇 |
2012年 | 44250篇 |
2011年 | 46914篇 |
2010年 | 27079篇 |
2009年 | 24923篇 |
2008年 | 42749篇 |
2007年 | 45075篇 |
2006年 | 45185篇 |
2005年 | 43603篇 |
2004年 | 41568篇 |
2003年 | 39427篇 |
2002年 | 38237篇 |
2001年 | 60734篇 |
2000年 | 62358篇 |
1999年 | 51925篇 |
1998年 | 13690篇 |
1997年 | 12269篇 |
1996年 | 12173篇 |
1995年 | 12360篇 |
1994年 | 11575篇 |
1993年 | 10841篇 |
1992年 | 41492篇 |
1991年 | 40751篇 |
1990年 | 39429篇 |
1989年 | 37319篇 |
1988年 | 34548篇 |
1987年 | 33677篇 |
1986年 | 32127篇 |
1985年 | 30631篇 |
1984年 | 22998篇 |
1983年 | 19527篇 |
1982年 | 11695篇 |
1981年 | 10225篇 |
1979年 | 20763篇 |
1978年 | 14771篇 |
1977年 | 12014篇 |
1976年 | 11835篇 |
1975年 | 12081篇 |
1974年 | 14776篇 |
1973年 | 14454篇 |
1972年 | 13350篇 |
1971年 | 12411篇 |
1970年 | 11475篇 |
1969年 | 10403篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
62.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
63.
64.
65.
66.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
67.
Schaff Lauren R. Yan Dongyao Thyparambil Sheeno Tian Yuan Cecchi Fabiola Rosenblum Marc Reiner Anne S. Panageas Katherine S. Hembrough Todd Lin Andrew L. 《Journal of neuro-oncology》2020,146(1):163-170
Journal of Neuro-Oncology - Understanding the molecular landscape of glioblastoma (GBM) is increasingly important in the age of targeted therapy. O-6-Methylguanine-DNA methyltransferase (MGMT)... 相似文献
68.
Babiker Hani M. Milhem Mohammed Aisner Joseph Edenfield William Shepard Dale Savona Michael Iyer Swaminathan Abdelrahim Maen Beach C. L. Skikne Barry Laille Eric Tsai Kao-Tai Ho Thai 《Cancer chemotherapy and pharmacology》2020,85(3):621-626
Cancer Chemotherapy and Pharmacology - CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize... 相似文献
69.
目的为研究DNA条形码技术在中成药鉴定中的应用,以三七片为研究对象,对方法的适用性、专属性与精密度进行考察。方法收集15批次市售三七片样品,考察三七片DNA提取条件,并对"中药材DNA条形码分子鉴定法指导原则"中PCR扩增、序列获得、结果判定等方法适用性进行确认;收集三七、人参、西洋参,制作三七片及其掺伪品,考察方法的专属性和重现性。结果三七片取样量100 mg,56℃水浴8 h所获得DNA的质量浓度平均值为60.7 ng/μL,PCR扩增、序列获得和结果判定均可获成功;三七、人参和西洋参的ITS2序列长度均为230bp,三七与人参、三七与西洋参的序列间均存在7个稳定的SNP位点,自制三七片和掺伪三七片均可成功获得ITS2序列,不同比例三七与人参、三七与西洋参的测序峰图在SNP位点处呈现相应峰高比的SNP套峰具备专属性;重复性、中间精密度和重现性考察符合《中国药典》2015年版(通则9101)相关要求。结论 ITS2序列作为DNA条形码能够稳定、准确鉴定三七片的原料药材,具备良好的专属性和精密度,三七片DNA条形码分子鉴定法将为保障三七片临床用药安全提供新的技术手段,并对《中国药典》其他收载单方制剂的鉴定提供参考。 相似文献
70.